Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease

J Urol. 1994 Aug;152(2 Pt 1):433-7. doi: 10.1016/s0022-5347(17)32757-x.


The androgen dihydrotestosterone is synthesized by the enzyme steroid 5 alpha-reductase, and it is required for growth and development of the prostate. We used immunohistochemistry to examine the expression of the type 2 isozyme of 5 alpha-reductase in benign prostatic hyperplasia and prostate cancer. The type 2 isozyme is highly expressed within stromal cells in both disease states. No type 2 isozyme is detectable in a lymph node metastasis. Immunoblotting studies show that androgen ablation therapies substantially decrease isozyme expression in the epididymis but have a lesser effect on expression in the prostate. Finasteride therapy (2 weeks to 3 years) did not abolish expression of the prostatic type 2 isozyme nor did this drug treatment induce expression of the type 1 isozyme.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 3-Oxo-5-alpha-Steroid 4-Dehydrogenase / analysis
  • 3-Oxo-5-alpha-Steroid 4-Dehydrogenase / biosynthesis*
  • 3-Oxo-5-alpha-Steroid 4-Dehydrogenase / classification
  • Adenocarcinoma / chemistry
  • Adenocarcinoma / metabolism*
  • Adenocarcinoma / pathology
  • Humans
  • Male
  • Middle Aged
  • Prostatic Hyperplasia / metabolism*
  • Prostatic Hyperplasia / pathology
  • Prostatic Neoplasms / chemistry
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms / pathology


  • 3-Oxo-5-alpha-Steroid 4-Dehydrogenase